Janssen's guselkumab beats placebo, Humira in psoriasis
This article was originally published in Scrip
Executive Summary
Janssen Biotech's "next generation" psoriasis therapy guselkumab met the primary endpoint versus placebo and bested AbbVie's blockbuster antibody therapeutic Humira (adalimumab) in the Phase IIb X-PLORE clinical trial.